Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PNPLA3 G was also associated with increased levels of ALT, except in participants with Dominican and South American backgrounds, and with liver fibrosis.
|
30743004 |
2019 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with nonalcoholic steatohepatitis (NASH), PNPLA3 GG compared to CC was associated with higher AST levels [38.4±25.3 versus 36.7±40.1IU/L, p=0.0395)] and with the presence of liver fibrosis (≥F2 fibrosis, p=0.0272).
|
31054980 |
2020 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of minor allele (G) of PNPLA3 was also associated with moderate/severe steatosis (≥33%) both in patients with (OR: 2.405 [CI95%: 1.220-4.744], P=0.011) and without MetS (OR: 2.481 [CI95%: 1.172-5.250], P=0.018), but was only associated with NASH (OR: 2.002 [CI95%: 1.062-3.772], P=0.032) and liver fibrosis (OR: 2.646 [CI95%: 1.299-5.389], P=0.007) in patients without MetS.
|
27908400 |
2017 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
PNPLA3 p.148M/M genotype was negatively associated with SVR and early viral kinetics independently of steatosis, albeit only in difficult-to-cure G1/4 patients with advanced fibrosis, whereas stratification for the p.148M/M PNPLA3 genotype unmasked an association between IL28B CC genotype and more severe liver fibrosis.
|
22530607 |
2012 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allelic variation (rs738409C→G) in adiponutrin (patatin-like phospholipase domain-containing protein 3, PNPLA3) has been associated with hepatic steatosis and liver fibrosis.
|
23418085 |
2013 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced liver fibrosis was neither associated with PNPLA3 (p = 0.253) nor IL28B-genotype (p = 0.628), but with HCV-GT3 (p = 0.003), higher BMI (p = 0.008) and higher age (p = 0.007).
|
26599080 |
2015 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fetuin B is independently and negatively associated with non-invasive markers of liver fibrosis and PNPLA3 status in NAFLD patients but does not show a correlation with the hepatic lipid content.
|
28914407 |
2017 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
These genetic variations also did not mediate the effect of <i>PNPLA3 rs738409</i> SNP for liver developing liver fibrosis or liver cirrhosis.
|
30875804 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to determine the association between PNPLA3 and liver fibrosis severity, HCC risk, and HCC prognosis among patients with liver disease.
|
24445574 |
2014 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide evidence to indicate that PNPLA3-mediated retinol release may protect against liver fibrosis by inducing a specific signature of proteins involved in extracellular matrix remodelling.
|
27742777 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
|
26765961 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs738409 C>G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis.
|
29956823 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we briefly highlight future research that may elucidate the specific mechanisms of the PNPLA3 I148M variant in fibrogenesis, which, in turn, provides a theoretical foundation and valuable experimental data for the clinical management of nonalcoholic fatty liver fibrosis.
|
25624712 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models.
|
28338112 |
2017 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, the common I148M variant of the PNPLA3 gene influencing hepatic lipid metabolism influences HCC risk independently of its effect on the progression of liver fibrosis.
|
25278690 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conversely, this enzymatic activity is markedly reduced with purified PNPLA3 148M, a common mutation robustly associated with liver fibrosis and hepatocellular carcinoma development.
|
24670599 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contradictory data about the impact of the rs738409 steatosis-related polymorphism within PNPLA3 gene on liver fibrosis progression in HIV/hepatitis C virus (HIV/HCV)-coinfected patients have been reported.
|
27973562 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients.
|
26760234 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism appears to be related to the increased progression of liver fibrosis in HCV infected patients.
|
29674183 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
|
20373368 |
2010 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To perform a comprehensive study on independent modulators of liver fibrosis progression and determinants of portal pressure considering immune status, insulin resistance (IR), serum 25-hydroxyvitamin D (25(OH)D) levels, genetic variants of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and interleukin 28B (IL28B) in a thoroughly documented cohort of HIV/hepatitis C-coinfected (HIV/HCV) patients.
|
24905495 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
|
30139224 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate models adjusting for histologic features of nonalcoholic steatohepatitis and liver fibrosis, PNPLA3 I148M is associated with a decrease in VLDL particle size.
|
28362682 |
2019 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.
|
24978903 |
2014 |